Title: Biochemist & Biomedical Engineer
Company: University of Texas Health Science Center at Houston (UTHealth)
Location: Houston, Texas, United States
Melvin E. Klegerman, Ph.D., Biochemist and Biomedical Engineer at the University of Texas Health Science Center at Houston (UTHealth), has been recognized by Marquis Who’s Who Top Scientists for dedication, achievements, and leadership in biomedical research.
With 45 years of professional experience, Dr. Klegerman is a prominent and respected biochemist and educator who has been a professor at the University of Texas at Houston since 2013 and president and chief executive officer at EchoDynamics, Inc., since 2000. Likewise, he is a founding member of Zymo Pharmaceuticals, LLC (Zymo Pharma), a role he has held since 2012. In his unique positions, he has conducted biomedical research on immunochemistry, immunoassay development, and conjugation chemistry, including participating in a collaborative study to develop targeted immunoliposomes for the diagnosis and treatment of cardiovascular diseases. Through UTHealth, Zymo Pharma and EchoDynamics, he intends to develop the echogenic liposome technology into clinical products.
Dr. Klegerman was encouraged to go into his field by his father, who was deeply involved in his life. In addition, he credits practicing Buddhism for 45 years for allowing him to remain focused and committed to overcoming obstacles. While coming from a background as a research associate is unusual in his line of work, it ended up benefitting Dr. Klegerman and how he approaches problems. He hopes that his unique approach to solving problems is a trait his peers will remember him by, as it has yielded insights that otherwise may not have been made. At the end of the day, the most rewarding aspect of his career is knowing the research and products he has helped develop and discover are helping people. He retains the belief that science is vital to civilization.
Dr. Klegerman is renowned for his work and United States patents for a method of Bacillus Calmette-Guerin (BCG) dispersal, his discovery of mycobacterial glucan anti-cancer properties, and the development of echogenic liposomes for the diagnosis and therapy of atherosclerosis. He has received multiple grants from such organizations as the National Institutes of Health and the World Health Organization, and he maintains affiliation with several industry-related societies, including the American Heart Association, the American Association of Pharmaceutical Scientists and the American Chemical Society. Notably, he has been a grantee of the National Institutes of Health since 1981.
Dr. Klegerman holds a Bachelor of Arts from the University of Illinois and a Doctor of Philosophy from Loyola University of Chicago. He also studied as a graduate student at the University of Chicago from 1969 to 1970 and was a research technician at the University from 1967 to 1969. Looking toward the future, he intends to work on getting a product into clinical trials and finishing his book, which is about a distinct perspective on the way in which scientists view evolution. He has been highlighted in several editions of Who’s Who in America, Who’s Who in Medicine and Healthcare, Who’s Who in Science and Engineering, and Who’s Who in the Midwest. In his spare time, he enjoys reading and volunteering for the Brazos Bend State Park near Houston.
Contact Dr. Klegerman